Orelabrutinib ( DrugBank: Orelabrutinib )
4 diseases
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 13 | Multiple sclerosis/Neuromyelitis optica | 3 |
| 49 | Systemic lupus erythematosus | 1 |
| 61 | Autoimmune hemolytic anemia | 1 |
| 63 | Idiopathic thrombocytopenic purpura | 2 |
13. Multiple sclerosis/Neuromyelitis optica
Clinical trials : 3,340 / Drugs : 2,163 - (DrugBank : 383) / Drug target genes : 241 - Drug target pathways : 238
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | ChiCTR2200057880 | 2022-04-01 | 2022-03-20 | A prospective, self-controlled study to explore efficacy and safety of orelabrutinib in AQP4-IgG positive neuromyelitis optica spectrum disorder | A prospective, self-controlled study to explore efficacy and safety of orelabrutinib in AQP4-IgG positive neuromyelitis optica spectrum disorder | Neuromyelitis optica spectrum disorder | Case group:Orelabrutinib, orally, 50 mg QD; | Peking Union Medical College Hospital | NULL | Pending | 18 | 75 | Both | Case group:23; | Phase 1 | China |
| 2 | NCT05284175 (ClinicalTrials.gov) | April 2022 | 9/3/2022 | A Study of Orelabrutinib in Patients With AQP4-IgG Positive Neuromyelitis Optica Spectrum Disorder | A Prospective, Self-controlled Study to Explore Efficacy and Safety of Orelabrutinib in AQP4-IgG Positive Neuromyelitis Optica Spectrum Disorder | Neuromyelitis Optica Spectrum Disorder | Drug: Orelabrutinib | Peking Union Medical College Hospital | Beijing InnoCare Pharma Tech Co., Ltd.;GCP ClinPlus Co., Ltd. | Not yet recruiting | 18 Years | 75 Years | All | 23 | N/A | China |
| 3 | NCT04711148 (ClinicalTrials.gov) | March 1, 2021 | 8/1/2021 | A Phase 2 Study of Orelabrutinib in Patients With Relapsing-Remitting Multiple Sclerosis | A Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Orelabrutinib in Patients With Relapsing-Remitting Multiple Sclerosis to Evaluate Efficacy, Safety, Tolerability, Pharmacokinetics, and Biological Activity | Relapsing Remitting Multiple Sclerosis | Other: placebo;Drug: orelabrutinib | Beijing InnoCare Pharma Tech Co., Ltd. | NULL | Active, not recruiting | 18 Years | 55 Years | All | 160 | Phase 2 | United States;China;Poland;Ukraine |
49. Systemic lupus erythematosus
Clinical trials : 993 / Drugs : 702 - (DrugBank : 184) / Drug target genes : 116 - Drug target pathways : 200
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05688696 (ClinicalTrials.gov) | March 31, 2023 | 10/1/2023 | Evaluate the Efficacy and Safety of Orelabrutinib in Adult Patients With Systemic Lupus Erythematosus | A Phase IIb, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Orelabrutinib in Adult Patients With Systemic Lupus Erythematosus | Systemic Lupus Erythematosus, SLE | Drug: Orelabrutinib (Low Dose);Drug: Orelabrutinib (High Dose);Drug: Orelabrutinib Placebo | Beijing InnoCare Pharma Tech Co., Ltd. | NULL | Not yet recruiting | 18 Years | 75 Years | All | 186 | Phase 2 | China |
61. Autoimmune hemolytic anemia
Clinical trials : 146 / Drugs : 131 - (DrugBank : 59) / Drug target genes : 28 - Drug target pathways : 158
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | ChiCTR2100045594 | 2021-04-19 | 2021-04-19 | A single center prospective clinical study of Orelabrutinib in the treatment of relapsed/refractory autoimmune hemolytic anemia/Evans syndrome | A single center prospective clinical study of Orelabrutinib in the treatment of recurrent refractory autoimmune hemolytic anemia/Evans syndrome | Relapsed/refractory autoimmune hemolytic anemia /Evans syndrome | Single arm:Orelabrutinib; | Tianjin Medical University General Hospital | NULL | Recruiting | Both | Single arm:20; | Phase 4 | China |
63. Idiopathic thrombocytopenic purpura
Clinical trials : 391 / Drugs : 235 - (DrugBank : 50) / Drug target genes : 49 - Drug target pathways : 139
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT05232149 (ClinicalTrials.gov) | February 21, 2022 | 20/12/2021 | A Study to Evaluate the Efficacy and Safety of Orelabrutinib in Adult Patients With Immune Thrombocytopenia | A Randomized, Multi-center, Adaptive Phase IIa/IIb Study to Evaluate the Efficacy and Safety of Orelabrutinib in Adult Patients With Persistent or Chronic Primary Immune Thrombocytopenia | Primary Immune Thrombocytopenia | Drug: Orelabrutinib( lower dose);Drug: Orelabrutinib( higher dose) | Beijing InnoCare Pharma Tech Co., Ltd. | NULL | Recruiting | 18 Years | 80 Years | All | 30 | Phase 2 | China |
| 2 | NCT05020288 (ClinicalTrials.gov) | September 1, 2021 | 12/8/2021 | A Clinical Trial of the Orelabrutinib in the Management of Refractory ITP | A Prospective, Open-label, Multicenter,Single-armed Study of Orelabrutinib in the Treatment of Refractory Primary Immune Thrombocytopenia (ITP) | Immune Thrombocytopenia;Bruton's Tyrosine Kinase | Drug: Orelabrutinib | Shandong University | NULL | Not yet recruiting | 18 Years | 70 Years | All | 40 | Phase 2 | NULL |